Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EP300 | Q09472 | 3/20 | 0.88 |
| ▸ | CHAT | P28329 | 2/20 | 0.88 |
| ▸ | NAA50 | Q9GZZ1 | 2/20 | 0.88 |
| ▸ | AURKA | O14965 | 2/20 | 0.88 |
| ▸ | KAT5 | Q92993 | 2/20 | 0.88 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.88 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14124919 | 0.96 | EP300 (0.86) | EP300CHATNAA50AURKAKAT5 | |
| Coenzyme_A SCHEMBL8048120 | 0.95 | AURKA (0.90) | EP300CHATNAA50AURKAKAT5 | |
| SCHEMBL14124848 | 0.95 | EP300 (0.86) | EP300CHATNAA50AURKAKAT5 | |
| SCHEMBL14124844 | 0.95 | EP300 (0.88) | EP300CHATNAA50AURKAKAT5 | |
| SCHEMBL4315276 | 0.95 | EP300 (0.90) | EP300CHATNAA50AURKAKAT5 | |
| SCHEMBL30583247 | 0.95 | EP300 (0.90) | EP300CHATNAA50AURKAKAT5 | |
| SCHEMBL16216007 | 0.95 | EP300 (0.89) | EP300CHATNAA50AURKAKAT5 | |
| SCHEMBL16215999 | 0.95 | EP300 (0.89) | EP300CHATNAA50AURKAKAT5 | |
| SCHEMBL14124928 | 0.94 | EP300 (0.86) | EP300CHATNAA50AURKAKAT5 | |
| SCHEMBL16585400 | 0.94 | NAA50 (0.84) | EP300CHATNAA50AURKAKAT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170362614-A1 | RECOMBINANT HOST CELLS FOR THE PRODUCTION OF MALONATE | LYGOS, INC. (US) | 2017-12-21 | — | — | US | disclosed |
| US-9816114-B2 | Recombinant host cells for the production of malonate | LYGOS, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-20170065601-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF MYCOBACTERIA | THE TEXAS A&M UNIVERSITY SYSTEM | 2017-03-09 | — | — | US | disclosed |
| US-20160177345-A1 | RECOMBINANT HOST CELLS FOR THE PRODUCTION OF MALONATE | LYGOS, INC. | 2016-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362614-A1 | RECOMBINANT HOST CELLS FOR THE PRODUCTION OF MALONATE | ME1, MAL2, ME3 | EP300 4075/4885CHAT 4633/4885NAA50 2396/4885 |
| US-20170065601-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF MYCOBACTERIA | ME3, PGLS, GNPAT | EP300 168/4885CHAT 924/4885NAA50 217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.